Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (7 quarters reported)
$224M in Q4 2024 → $643M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Cg Oncology, Inc. | 26.2% | Added 6.7% | 2,369,574 | $168M |
| Alumis Inc. | 18.6% | Unchanged | 4,247,670 | $120M |
| Seaport Therapeutics, Inc. | 6.0% | New | 1,779,521 | $38.7M |
| Denali Therapeutics Inc. | 5.6% | Added 15% | 1,396,771 | $35.9M |
| Celldex Therapeutics, Inc. | 5.1% | Added 178% | 879,713 | $32.7M |
| Agios Pharmaceuticals, Inc. | 4.5% | Added 50% | 785,000 | $29.1M |
| Corvus Pharmaceuticals, Inc. | 4.3% | Unchanged | 1,831,233 | $27.4M |
| PM Parabilis Medicines, Inc. | 4.3% | New | 999,044 | $27.3M |
| Gh Research PLC | 3.9% | Added 198% | 940,493 | $25.3M |
| Jade Biosciences, Inc. | 3.1% | Added 177% | 886,667 | $19.7M |
| Hinge Health, Inc. | 2.8% | Unchanged | 220,400 | $18.3M |
| Kymera Therapeutics, Inc. | 2.6% | Unchanged | 146,332 | $16.8M |
| Ataibeckley Inc. | 2.3% | Unchanged | 2,750,000 | $14.5M |
| Verastem, Inc. | 1.9% | Unchanged | 3,146,631 | $12M |
| Beam Therapeutics Inc. | 1.8% | New | 330,000 | $11.3M |
| Minerva Neurosciences, Inc. | 1.7% | Trimmed 0.1% | 1,985,584 | $11M |
| Arrivent Biopharma, Inc. | 1.6% | New | 301,341 | $10.5M |
| Aura Biosciences, Inc. | 1.5% | New | 1,333,334 | $9.47M |
| Crinetics Pharmaceuticals, Inc. | 1.2% | Unchanged | 212,010 | $7.93M |
| RA Research Alliance Corp Iii | 0.5% | New | 300,000 | $3.21M |
| Zura Bio Ltd | 0.4% | Unchanged | 450,000 | $2.66M |
| Kailera Therapeutics, Inc. | 0.1% | New | 37,500 | $826K |
| Disc Medicine, Inc. | 0.0% | New | 970 | $70.9K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 6 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Centessa Pharmaceuticals PLC | Exited | −1,364,019 | −$54.2M | — |
| Seaport Therapeutics, Inc. | New | +1,779,521 | +$38.7M | 6.0% |
| PM Parabilis Medicines, Inc. | New | +999,044 | +$27.3M | 4.3% |
| Celldex Therapeutics, Inc. | Added | +563,800 | +$21M | 5.1% |
| Gh Research PLC | Added | +625,001 | +$16.8M | 3.9% |
| Jade Biosciences, Inc. | Added | +566,667 | +$12.6M | 3.1% |
| Beam Therapeutics Inc. | New | +330,000 | +$11.3M | 1.8% |
| Cg Oncology, Inc. | Added | +148,100 | +$10.5M | 26.2% |
| Arrivent Biopharma, Inc. | New | +301,341 | +$10.5M | 1.6% |
| Agios Pharmaceuticals, Inc. | Added | +260,000 | +$9.65M | 4.5% |
Showing the 10 largest of 17 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Rapt Therapeutics, Inc. | Exited | −1,562,500 | −$52.9M | — |
| Natera, Inc. | Exited | −67,356 | −$15.4M | — |
| Minerva Neurosciences, Inc. | New | +1,986,600 | +$12M | 2.6% |
| Atai Beckley N.v. | Exited | −2,750,000 | −$11.2M | — |
| Celldex Therapeutics, Inc. | New | +315,913 | +$10M | 2.2% |
| Ataibeckley Inc. | New | +2,750,000 | +$9.74M | 2.1% |
| Crinetics Pharmaceuticals, Inc. | New | +212,010 | +$7.7M | 1.7% |
| Corvus Pharmaceuticals, Inc. | Added | +450,000 | +$6.58M | 5.8% |
| Onkure Therapeutics, Inc. | New | +1,445,783 | +$5.99M | 1.3% |
| Jade Biosciences, Inc. | New | +320,000 | +$4.5M | 1.0% |
Showing the 10 largest of 16 changes.
quarter ended December 31, 2025 · filed February 17, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Natera, Inc. | New | +67,356 | +$15.4M | 4.7% |
| Agios Pharmaceuticals, Inc. | New | +530,000 | +$14.4M | 4.4% |
| Akero Therapeutics, Inc. | Exited | −244,900 | −$11.6M | — |
| Atai Beckley N.v. | New | +2,750,000 | +$11.2M | 3.4% |
| Verastem, Inc. | Added | +520,000 | +$4.01M | 7.3% |
| Corvus Pharmaceuticals, Inc. | Trimmed | −350,000 | −$2.7M | 3.2% |
| Avidity Biosciences, Inc. | Exited | −40,000 | −$1.74M | — |
| Casi Pharmaceuticals, Inc. | Exited | −979,956 | −$1.63M | — |
| Centessa Pharmaceuticals PLC | Added | +50,000 | +$1.25M | 10.3% |
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Denali Therapeutics Inc. | New | +1,000,000 | +$14.5M | 5.6% |
| Verastem, Inc. | Added | +1,338,600 | +$11.8M | 8.9% |
| Bicara Therapeutics Inc | Exited | −949,260 | −$8.82M | — |
| Edgewise Therapeutics Inc | Exited | −585,000 | −$7.67M | — |
| Xenon Pharmaceuticals Inc | Exited | −160,000 | −$5.01M | — |
| Cullinan Therapeutics Inc | Exited | −594,025 | −$4.47M | — |
| Structure Therapeutics Inc | Exited | −210,000 | −$4.36M | — |
| Allogene Therapeutics Inc | Exited | −2,875,357 | −$3.25M | — |
| Ideaya Biosciences Inc | Exited | −144,468 | −$3.04M | — |
| Centessa Pharmaceuticals PLC | Added | +60,640 | +$1.47M | 12.3% |
Showing the 10 largest of 13 changes.
quarter ended June 30, 2025 · filed August 12, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Rapt Therapeutics Inc | Exited | −12,500,000 | −$15.3M | — |
| Rapt Therapeutics Inc | New | +1,562,500 | +$12.5M | 7.0% |
| Hinge Health Inc | New | +135,000 | +$6.99M | 3.9% |
| Akero Therapeutics Inc | Trimmed | −120,100 | −$6.41M | 7.3% |
| Verastem Inc | New | +1,276,520 | +$5.3M | 3.0% |
| Xenon Pharmaceuticals Inc | New | +160,000 | +$5.01M | 2.8% |
| Structure Therapeutics Inc | Trimmed | −210,000 | −$4.36M | 2.4% |
| Ideaya Biosciences Inc | New | +144,468 | +$3.04M | 1.7% |
| Avidity Biosciences Inc | New | +40,000 | +$1.14M | 0.6% |
| Spyre Therapeutics Inc | New | +70,000 | +$1.05M | 0.6% |
Showing the 10 largest of 16 changes.
quarter ended March 31, 2025 · filed May 15, 2025
No position changes this quarter.
Loading...
